Western Asset Municipal Partners Fund Inc. (MNP) At $14.23 Forms Bottom; Shorts at Azurrx Biopharma (AZRX) Raised By 141.45%

Western Asset Municipal Partners Fund Inc. (MNP) formed multiple bottom with $13.38 target or 6.00% below today’s $14.23 share price. Western Asset Municipal Partners Fund Inc. (MNP) has $138.30 million valuation. The stock increased 0.14% or $0.02 during the last trading session, reaching $14.23. About 15,657 shares traded. Western Asset Municipal Partners Fund Inc. (NYSE:MNP) has declined 9.90% since June 25, 2017 and is downtrending. It has underperformed by 22.47% the S&P500.

Azurrx Biopharma Inc (NASDAQ:AZRX) had an increase of 141.45% in short interest. AZRX’s SI was 36,700 shares in June as released by FINRA. Its up 141.45% from 15,200 shares previously. With 42,300 avg volume, 1 days are for Azurrx Biopharma Inc (NASDAQ:AZRX)’s short sellers to cover AZRX’s short positions. The SI to Azurrx Biopharma Inc’s float is 0.62%. The stock increased 3.59% or $0.12 during the last trading session, reaching $3.46. About 40,025 shares traded. AzurRx BioPharma, Inc. (NASDAQ:AZRX) has declined 33.33% since June 25, 2017 and is downtrending. It has underperformed by 45.90% the S&P500. Some Historical AZRX News: 23/04/2018 – AZURRX BIOPHARMA INC – OBSERVED BOTH CLINICAL ACTIVITY AND A CLEAR DOSE RESPONSE IN ITS ONGOING PHASE llA TRIAL OF MS1819-SD; 18/04/2018 AzurRx BioPharma Announces Positive Preclinical Data with AZX1103; 23/04/2018 – AZURRX BIOPHARMA INC – MAXIMAL ABSOLUTE CFA RESPONSE TO TREATMENT WAS UP TO 57%, WITH AN INVERSE RELATIONSHIP TO BASELINE CFA; 18/04/2018 – AZURRX BIOPHARMA INC – AZX1103 SHOWN TO BE SAFE AND BIOLOGICALLY ACTIVE IN A WELL-ESTABLISHED PRE-CLINICAL MODEL; 23/04/2018 – AZURRX BIOPHARMA INC – HIGHEST MS1819-SD DOSE COHORT CONTINUED TO SHOW GREATER THAN 21% IMPROVEMENT IN CFA IN EVALUABLE PATIENTS; 23/04/2018 – AZURRX BIOPHARMA AND MAYOLY-SPINDLER ANNOUNCE ADDITIONAL POSITIVE INTERIM DATA FOR MS1819-SD PHASE Il IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI); 23/04/2018 – AzurRx BioPharma and Mayoly-Spindler Announce Additional Positive Interim Data for MS1819-SD Phase Il in Exocrine Pancreatic lnsufficiency (EPI); 18/04/2018 – AZURRX BIOPHARMA – PRECLINICAL STUDIES INVESTIGATED ORAL DELIVERY OF AZ1103 USING THREE CAPSULE FORMULATIONS, ALL APPEARING TO BE WELL TOLERATED; 23/04/2018 – AZURRX BIOPHARMA INC – NO SERIOUS ADVERSE EVENTS OR NOTABLE MILD TO MODERATE EVENTS HAVE BEEN REPORTED IN PHASE llA TRIAL; 11/05/2018 – HIGHBRIDGE CAPITAL MANAGEMENT LLC REPORTS 5.97 PCT PASSIVE STAKE IN AZURRX BIOPHARMA INC AS OF MAY 1, 2018 – SEC FILING

More important recent AzurRx BioPharma, Inc. (NASDAQ:AZRX) news were published by: Benzinga.com which released: “36 Biggest Movers From Friday” on June 11, 2018, also Benzinga.com published article titled: “30 Stocks Moving In Friday’s Mid-Day Session”, Globenewswire.com published: “AzurRx Announces Appointment of Dr. James Pennington as Chief Medical Officer” on May 30, 2018. More interesting news about AzurRx BioPharma, Inc. (NASDAQ:AZRX) was released by: Benzinga.com and their article: “45 Biggest Movers From Yesterday” with publication date: June 08, 2018.

AzurRx BioPharma, Inc., a clinical development stage biopharmaceutical company, engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. The company has market cap of $58.00 million. The Company’s product pipeline consists of two therapeutic proteins under development, including MS1819, an autologous yeast recombinant lipase, which is in Phase IIa trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, a recombinant b-lactamase combination of bacterial origin for the prevention of hospital-acquired infections, as well as antibiotic-associated diarrhea. It currently has negative earnings.

Investors sentiment decreased to 1.36 in Q1 2018. Its down 0.08, from 1.44 in 2017Q4. It is negative, as 4 investors sold Western Asset Municipal Partners Fund Inc. shares while 7 reduced holdings. 5 funds opened positions while 10 raised stakes. 1.45 million shares or 12.43% more from 1.29 million shares in 2017Q4 were reported. Wolverine Asset Limited Com holds 0.01% of its portfolio in Western Asset Municipal Partners Fund Inc. (NYSE:MNP) for 29,252 shares. Advisors Asset Management reported 0.04% stake. Ameriprise Fincl reported 0% in Western Asset Municipal Partners Fund Inc. (NYSE:MNP). Raymond James Trust Na stated it has 37,871 shares. New Jersey-based Landscape Mgmt Limited Liability has invested 0.02% in Western Asset Municipal Partners Fund Inc. (NYSE:MNP). Guggenheim Cap Lc reported 30,149 shares. Pnc Financial Grp Incorporated owns 0% invested in Western Asset Municipal Partners Fund Inc. (NYSE:MNP) for 508 shares. Sit Invest Assocs Inc invested 0.01% of its portfolio in Western Asset Municipal Partners Fund Inc. (NYSE:MNP). Financial Bank Of America De reported 0% of its portfolio in Western Asset Municipal Partners Fund Inc. (NYSE:MNP). Wells Fargo & Mn holds 29,716 shares or 0% of its portfolio. 74,286 were accumulated by Morgan Stanley. Nuveen Asset Mgmt Ltd Liability Com owns 22,529 shares. Vantage Advsr Limited has 0.01% invested in Western Asset Municipal Partners Fund Inc. (NYSE:MNP). Dixon Hubard Feinour Brown Va owns 14,650 shares for 0.06% of their portfolio. First Tru Advisors Limited Partnership owns 84,084 shares.

AzurRx BioPharma, Inc. (NASDAQ:AZRX) Ratings Chart